Pfizer Animal Health is seeking research proposals to support the continued study of the clinical efficacy of DRAXXIN (tulathromycin) injectable solution, a macrolide for the treatment of swine respiratory disease. 


Pfizer Animal Health will provide up to four grants, $100,000 in total, for clinical research on the use of DRAXXIN as part of an overall disease treatment and control plan that demonstrates a direct benefit to swine health. DRAXXIN will be provided to study investigators at no cost. The deadline for grant proposal submission is November 15.